nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—Conduction disorder—Hydrochlorothiazide—nephrolithiasis	0.0334	0.0611	CcSEcCtD
Clomipramine—GSTP1—urine—nephrolithiasis	0.0208	0.172	CbGeAlD
Clomipramine—Local swelling—Hydrochlorothiazide—nephrolithiasis	0.0201	0.0366	CcSEcCtD
Clomipramine—CYP2C19—urine—nephrolithiasis	0.0143	0.119	CbGeAlD
Clomipramine—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.0125	0.0228	CcSEcCtD
Clomipramine—CYP1A2—urine—nephrolithiasis	0.0117	0.0969	CbGeAlD
Clomipramine—Encephalopathy—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0199	CcSEcCtD
Clomipramine—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0192	CcSEcCtD
Clomipramine—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00915	0.0167	CcSEcCtD
Clomipramine—HTR2A—urine—nephrolithiasis	0.00914	0.0757	CbGeAlD
Clomipramine—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00893	0.0163	CcSEcCtD
Clomipramine—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.00865	0.0158	CcSEcCtD
Clomipramine—CYP3A4—urine—nephrolithiasis	0.00847	0.0701	CbGeAlD
Clomipramine—CYP2D6—urine—nephrolithiasis	0.00833	0.069	CbGeAlD
Clomipramine—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.00792	0.0145	CcSEcCtD
Clomipramine—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00776	0.0142	CcSEcCtD
Clomipramine—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00755	0.0138	CcSEcCtD
Clomipramine—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00755	0.0138	CcSEcCtD
Clomipramine—Gout—Hydrochlorothiazide—nephrolithiasis	0.0075	0.0137	CcSEcCtD
Clomipramine—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00741	0.0135	CcSEcCtD
Clomipramine—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00713	0.013	CcSEcCtD
Clomipramine—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00713	0.013	CcSEcCtD
Clomipramine—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00701	0.0128	CcSEcCtD
Clomipramine—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.0064	0.0117	CcSEcCtD
Clomipramine—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00633	0.0116	CcSEcCtD
Clomipramine—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00587	0.0107	CcSEcCtD
Clomipramine—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00585	0.0107	CcSEcCtD
Clomipramine—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00579	0.0106	CcSEcCtD
Clomipramine—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00579	0.0106	CcSEcCtD
Clomipramine—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00568	0.0104	CcSEcCtD
Clomipramine—GSTP1—nephron tubule—nephrolithiasis	0.00559	0.0463	CbGeAlD
Clomipramine—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00544	0.00994	CcSEcCtD
Clomipramine—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00541	0.00989	CcSEcCtD
Clomipramine—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00539	0.00985	CcSEcCtD
Clomipramine—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00534	0.00977	CcSEcCtD
Clomipramine—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00528	0.00964	CcSEcCtD
Clomipramine—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00509	0.0093	CcSEcCtD
Clomipramine—GSTP1—renal system—nephrolithiasis	0.00508	0.0421	CbGeAlD
Clomipramine—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00501	0.00915	CcSEcCtD
Clomipramine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00501	0.00915	CcSEcCtD
Clomipramine—GSTP1—kidney—nephrolithiasis	0.00491	0.0407	CbGeAlD
Clomipramine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00482	0.00881	CcSEcCtD
Clomipramine—GSTP1—cortex of kidney—nephrolithiasis	0.00478	0.0396	CbGeAlD
Clomipramine—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00478	0.00874	CcSEcCtD
Clomipramine—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00466	0.00852	CcSEcCtD
Clomipramine—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00464	0.00849	CcSEcCtD
Clomipramine—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00463	0.00846	CcSEcCtD
Clomipramine—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.0046	0.0084	CcSEcCtD
Clomipramine—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.0045	0.00823	CcSEcCtD
Clomipramine—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00449	0.0082	CcSEcCtD
Clomipramine—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0044	0.0144	CbGpPWpGaD
Clomipramine—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.0044	0.00803	CcSEcCtD
Clomipramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00425	0.0139	CbGpPWpGaD
Clomipramine—ADRA2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00414	0.0135	CbGpPWpGaD
Clomipramine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00411	0.00751	CcSEcCtD
Clomipramine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00406	0.00742	CcSEcCtD
Clomipramine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00405	0.0074	CcSEcCtD
Clomipramine—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00401	0.00733	CcSEcCtD
Clomipramine—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.004	0.00731	CcSEcCtD
Clomipramine—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00396	0.00725	CcSEcCtD
Clomipramine—HTR2B—cortex of kidney—nephrolithiasis	0.00394	0.0327	CbGeAlD
Clomipramine—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00394	0.00721	CcSEcCtD
Clomipramine—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00386	0.00706	CcSEcCtD
Clomipramine—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00384	0.00702	CcSEcCtD
Clomipramine—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00384	0.00702	CcSEcCtD
Clomipramine—HTR2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00382	0.0125	CbGpPWpGaD
Clomipramine—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00382	0.00698	CcSEcCtD
Clomipramine—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00381	0.00696	CcSEcCtD
Clomipramine—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00381	0.00696	CcSEcCtD
Clomipramine—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00376	0.00687	CcSEcCtD
Clomipramine—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00374	0.00683	CcSEcCtD
Clomipramine—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.0037	0.00676	CcSEcCtD
Clomipramine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00368	0.00672	CcSEcCtD
Clomipramine—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00366	0.00668	CcSEcCtD
Clomipramine—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00655	CcSEcCtD
Clomipramine—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00357	0.0117	CbGpPWpGaD
Clomipramine—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00353	0.00645	CcSEcCtD
Clomipramine—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00352	0.00643	CcSEcCtD
Clomipramine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.0035	0.0064	CcSEcCtD
Clomipramine—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00349	0.00638	CcSEcCtD
Clomipramine—ADRA2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00348	0.0114	CbGpPWpGaD
Clomipramine—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00339	0.0062	CcSEcCtD
Clomipramine—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00328	0.006	CcSEcCtD
Clomipramine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00597	CcSEcCtD
Clomipramine—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00314	0.00574	CcSEcCtD
Clomipramine—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00311	0.00568	CcSEcCtD
Clomipramine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00307	0.01	CbGpPWpGaD
Clomipramine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00302	0.00552	CcSEcCtD
Clomipramine—Propiomazine—CHRM3—nephrolithiasis	0.00301	0.113	CrCbGaD
Clomipramine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00301	0.00549	CcSEcCtD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.003	0.00982	CbGpPWpGaD
Clomipramine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.003	0.00548	CcSEcCtD
Clomipramine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00297	0.00544	CcSEcCtD
Clomipramine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00296	0.00541	CcSEcCtD
Clomipramine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00294	0.00538	CcSEcCtD
Clomipramine—HRH2—G alpha (s) signalling events—PTH—nephrolithiasis	0.00294	0.00962	CbGpPWpGaD
Clomipramine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00289	0.00528	CcSEcCtD
Clomipramine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00287	0.00524	CcSEcCtD
Clomipramine—CYP1A2—renal system—nephrolithiasis	0.00286	0.0237	CbGeAlD
Clomipramine—Chlorprothixene—CHRM3—nephrolithiasis	0.00285	0.107	CrCbGaD
Clomipramine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00519	CcSEcCtD
Clomipramine—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00283	0.00517	CcSEcCtD
Clomipramine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00281	0.00514	CcSEcCtD
Clomipramine—Nortriptyline—CHRM3—nephrolithiasis	0.00279	0.105	CrCbGaD
Clomipramine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00276	0.00505	CcSEcCtD
Clomipramine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00275	0.00503	CcSEcCtD
Clomipramine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00275	0.00502	CcSEcCtD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00274	0.00898	CbGpPWpGaD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00274	0.00898	CbGpPWpGaD
Clomipramine—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00274	0.00501	CcSEcCtD
Clomipramine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00271	0.00495	CcSEcCtD
Clomipramine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00269	0.00492	CcSEcCtD
Clomipramine—Cough—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00488	CcSEcCtD
Clomipramine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00477	CcSEcCtD
Clomipramine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00477	CcSEcCtD
Clomipramine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00477	CcSEcCtD
Clomipramine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00475	CcSEcCtD
Clomipramine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00258	0.00471	CcSEcCtD
Clomipramine—Methotrimeprazine—CHRM3—nephrolithiasis	0.00257	0.0965	CrCbGaD
Clomipramine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00466	CcSEcCtD
Clomipramine—Promethazine—CHRM3—nephrolithiasis	0.00253	0.0951	CrCbGaD
Clomipramine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00252	0.00461	CcSEcCtD
Clomipramine—Doxepin—CHRM3—nephrolithiasis	0.00251	0.0941	CrCbGaD
Clomipramine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00457	CcSEcCtD
Clomipramine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00457	CcSEcCtD
Clomipramine—ADRA2A—cortex of kidney—nephrolithiasis	0.00248	0.0205	CbGeAlD
Clomipramine—Shock—Hydrochlorothiazide—nephrolithiasis	0.00246	0.00449	CcSEcCtD
Clomipramine—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00447	CcSEcCtD
Clomipramine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00446	CcSEcCtD
Clomipramine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00242	0.00442	CcSEcCtD
Clomipramine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00435	CcSEcCtD
Clomipramine—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00234	0.00427	CcSEcCtD
Clomipramine—Desipramine—CHRM3—nephrolithiasis	0.0023	0.0864	CrCbGaD
Clomipramine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00228	0.00416	CcSEcCtD
Clomipramine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00226	0.00413	CcSEcCtD
Clomipramine—HTR6—G alpha (s) signalling events—PTH—nephrolithiasis	0.00225	0.00738	CbGpPWpGaD
Clomipramine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00224	0.0041	CcSEcCtD
Clomipramine—HTR2B—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00224	0.00733	CbGpPWpGaD
Clomipramine—HTR2A—renal system—nephrolithiasis	0.00224	0.0185	CbGeAlD
Clomipramine—Promazine—CHRM3—nephrolithiasis	0.00223	0.0837	CrCbGaD
Clomipramine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00223	0.00407	CcSEcCtD
Clomipramine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00406	CcSEcCtD
Clomipramine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00402	CcSEcCtD
Clomipramine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00217	0.00397	CcSEcCtD
Clomipramine—HTR2A—kidney—nephrolithiasis	0.00216	0.0179	CbGeAlD
Clomipramine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00215	0.00394	CcSEcCtD
Clomipramine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00391	CcSEcCtD
Clomipramine—Pain—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00391	CcSEcCtD
Clomipramine—ADRA2A—Regulation of insulin secretion—CHRM3—nephrolithiasis	0.0021	0.00687	CbGpPWpGaD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00208	0.00681	CbGpPWpGaD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00208	0.00681	CbGpPWpGaD
Clomipramine—CYP3A4—renal system—nephrolithiasis	0.00207	0.0172	CbGeAlD
Clomipramine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00206	0.00376	CcSEcCtD
Clomipramine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00204	0.00374	CcSEcCtD
Clomipramine—CYP2D6—renal system—nephrolithiasis	0.00204	0.0169	CbGeAlD
Clomipramine—HTR2A—GPCRs, Other—CHRM3—nephrolithiasis	0.00202	0.00661	CbGpPWpGaD
Clomipramine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.002	0.00656	CbGpPWpGaD
Clomipramine—CYP3A4—kidney—nephrolithiasis	0.002	0.0166	CbGeAlD
Clomipramine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00199	0.00363	CcSEcCtD
Clomipramine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00198	0.00361	CcSEcCtD
Clomipramine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00198	0.00361	CcSEcCtD
Clomipramine—CYP2D6—kidney—nephrolithiasis	0.00197	0.0163	CbGeAlD
Clomipramine—Chlorpromazine—CHRM3—nephrolithiasis	0.00196	0.0736	CrCbGaD
Clomipramine—Imipramine—CHRM3—nephrolithiasis	0.00195	0.0732	CrCbGaD
Clomipramine—Amitriptyline—CHRM3—nephrolithiasis	0.00194	0.0728	CrCbGaD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00193	0.00633	CbGpPWpGaD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00193	0.00633	CbGpPWpGaD
Clomipramine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00184	0.00337	CcSEcCtD
Clomipramine—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00181	0.00592	CbGpPWpGaD
Clomipramine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00179	0.00328	CcSEcCtD
Clomipramine—HRH2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00179	0.00585	CbGpPWpGaD
Clomipramine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00323	CcSEcCtD
Clomipramine—ADRA2A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00176	0.00576	CbGpPWpGaD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00172	0.00564	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00171	0.0056	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00171	0.0056	CbGpPWpGaD
Clomipramine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00171	0.00313	CcSEcCtD
Clomipramine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00165	0.00302	CcSEcCtD
Clomipramine—ADRA2A—Integration of energy metabolism—CHRM3—nephrolithiasis	0.00165	0.0054	CbGpPWpGaD
Clomipramine—HTR2B—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00162	0.0053	CbGpPWpGaD
Clomipramine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00162	0.00529	CbGpPWpGaD
Clomipramine—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.00162	0.00529	CbGpPWpGaD
Clomipramine—ABCB1—nephron tubule—nephrolithiasis	0.00161	0.0134	CbGeAlD
Clomipramine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00159	0.0029	CcSEcCtD
Clomipramine—Rash—Hydrochlorothiazide—nephrolithiasis	0.00158	0.00288	CcSEcCtD
Clomipramine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00157	0.00288	CcSEcCtD
Clomipramine—HTR2A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00157	0.00514	CbGpPWpGaD
Clomipramine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00157	0.00286	CcSEcCtD
Clomipramine—HRH2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00153	0.00502	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00152	0.00499	CbGpPWpGaD
Clomipramine—ALB—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00151	0.00493	CbGpPWpGaD
Clomipramine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00148	0.00271	CcSEcCtD
Clomipramine—ABCB1—renal system—nephrolithiasis	0.00147	0.0121	CbGeAlD
Clomipramine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00145	0.00474	CbGpPWpGaD
Clomipramine—ABCB1—kidney—nephrolithiasis	0.00142	0.0117	CbGeAlD
Clomipramine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0014	0.0046	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00139	0.00456	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00139	0.00456	CbGpPWpGaD
Clomipramine—ABCB1—cortex of kidney—nephrolithiasis	0.00138	0.0114	CbGeAlD
Clomipramine—ALB—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00138	0.00451	CbGpPWpGaD
Clomipramine—ALB—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00138	0.00451	CbGpPWpGaD
Clomipramine—HTR6—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00137	0.00449	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00135	0.00442	CbGpPWpGaD
Clomipramine—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00131	0.00428	CbGpPWpGaD
Clomipramine—HTR2B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00125	0.0041	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00125	0.00409	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—RGS14—nephrolithiasis	0.00123	0.00401	CbGpPWpGaD
Clomipramine—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.00121	0.00397	CbGpPWpGaD
Clomipramine—HTR6—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00118	0.00385	CbGpPWpGaD
Clomipramine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00117	0.00383	CbGpPWpGaD
Clomipramine—HRH2—GPCR ligand binding—CHRM3—nephrolithiasis	0.00117	0.00382	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—GRHPR—nephrolithiasis	0.00116	0.0038	CbGpPWpGaD
Clomipramine—HTR2A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00114	0.00371	CbGpPWpGaD
Clomipramine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00112	0.00365	CbGpPWpGaD
Clomipramine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00107	0.00351	CbGpPWpGaD
Clomipramine—HRH2—GPCR ligand binding—PTH—nephrolithiasis	0.00107	0.00349	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00106	0.00346	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00106	0.00346	CbGpPWpGaD
Clomipramine—ALB—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00105	0.00342	CbGpPWpGaD
Clomipramine—ALB—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00105	0.00342	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—RGS14—nephrolithiasis	0.00104	0.00339	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—AGXT—nephrolithiasis	0.00103	0.00339	CbGpPWpGaD
Clomipramine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00102	0.00332	CbGpPWpGaD
Clomipramine—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00101	0.00331	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000986	0.00323	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000982	0.00322	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000982	0.00322	CbGpPWpGaD
Clomipramine—ALB—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000972	0.00318	CbGpPWpGaD
Clomipramine—ALB—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000972	0.00318	CbGpPWpGaD
Clomipramine—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.000946	0.0031	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—RGS14—nephrolithiasis	0.000945	0.00309	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—RGS14—nephrolithiasis	0.000941	0.00308	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000912	0.00299	CbGpPWpGaD
Clomipramine—HTR6—GPCR ligand binding—CHRM3—nephrolithiasis	0.000895	0.00293	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—SLC26A1—nephrolithiasis	0.00088	0.00288	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—APRT—nephrolithiasis	0.00088	0.00288	CbGpPWpGaD
Clomipramine—HTR2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000877	0.00287	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000876	0.00287	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000876	0.00287	CbGpPWpGaD
Clomipramine—ALB—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000866	0.00283	CbGpPWpGaD
Clomipramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000866	0.00283	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00086	0.00281	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00086	0.00281	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—RGS14—nephrolithiasis	0.000859	0.00281	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—ADCY10—nephrolithiasis	0.000852	0.00279	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—DGKH—nephrolithiasis	0.000828	0.00271	CbGpPWpGaD
Clomipramine—HTR6—GPCR ligand binding—PTH—nephrolithiasis	0.000819	0.00268	CbGpPWpGaD
Clomipramine—HTR2B—GPCR ligand binding—CHRM3—nephrolithiasis	0.000817	0.00267	CbGpPWpGaD
Clomipramine—ADRA2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000798	0.00261	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000766	0.00251	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.000763	0.0025	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000753	0.00247	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000753	0.00247	CbGpPWpGaD
Clomipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000752	0.00246	CbGpPWpGaD
Clomipramine—HTR2B—GPCR ligand binding—PTH—nephrolithiasis	0.000747	0.00245	CbGpPWpGaD
Clomipramine—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.00073	0.00239	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—RGS14—nephrolithiasis	0.000724	0.00237	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000701	0.00229	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000701	0.00229	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.0007	0.00229	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—DGKH—nephrolithiasis	0.0007	0.00229	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	0.000693	0.00227	CbGpPWpGaD
Clomipramine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000684	0.00224	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000671	0.0022	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000662	0.00217	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00066	0.00216	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.000659	0.00216	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—ADCY10—nephrolithiasis	0.000653	0.00214	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—DGKH—nephrolithiasis	0.000644	0.00211	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—SLC7A9—nephrolithiasis	0.000644	0.00211	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—DGKH—nephrolithiasis	0.000639	0.00209	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—DGKH—nephrolithiasis	0.000635	0.00208	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—AQP1—nephrolithiasis	0.000627	0.00205	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000614	0.00201	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000614	0.00201	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—PTH—nephrolithiasis	0.000603	0.00197	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	0.000603	0.00197	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000603	0.00197	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—RGS14—nephrolithiasis	0.000602	0.00197	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000599	0.00196	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—ADCY10—nephrolithiasis	0.000597	0.00195	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—DGKH—nephrolithiasis	0.00058	0.0019	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000572	0.00187	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—CHRM3—nephrolithiasis	0.000567	0.00186	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—RGS14—nephrolithiasis	0.000556	0.00182	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—PTH—nephrolithiasis	0.000548	0.00179	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—RGS14—nephrolithiasis	0.000547	0.00179	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000531	0.00174	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000531	0.00174	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—PTH—nephrolithiasis	0.000524	0.00171	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000521	0.0017	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.000515	0.00169	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—DGKH—nephrolithiasis	0.000508	0.00166	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—SLC7A9—nephrolithiasis	0.000508	0.00166	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—RGS14—nephrolithiasis	0.000507	0.00166	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000506	0.00166	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000494	0.00162	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000494	0.00162	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000489	0.0016	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—DGKH—nephrolithiasis	0.000489	0.0016	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000481	0.00158	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—PTH—nephrolithiasis	0.000476	0.00156	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	0.000468	0.00153	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000465	0.00152	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000465	0.00152	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—PTH—nephrolithiasis	0.000463	0.00151	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000462	0.00151	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—CHRM3—nephrolithiasis	0.000459	0.0015	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000447	0.00146	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00044	0.00144	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00044	0.00144	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000433	0.00142	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000433	0.00142	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—PTH—nephrolithiasis	0.000422	0.00138	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—PTH—nephrolithiasis	0.00042	0.00138	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—CHRM3—nephrolithiasis	0.000419	0.00137	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000418	0.00137	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	0.000409	0.00134	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000407	0.00133	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—DGKH—nephrolithiasis	0.000406	0.00133	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—GRHPR—nephrolithiasis	0.000387	0.00127	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000386	0.00126	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000386	0.00126	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—PTH—nephrolithiasis	0.000384	0.00126	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ADCY10—nephrolithiasis	0.00038	0.00124	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000375	0.00123	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—DGKH—nephrolithiasis	0.000375	0.00123	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000373	0.00122	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—DGKH—nephrolithiasis	0.00037	0.00121	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—RGS14—nephrolithiasis	0.000355	0.00116	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CHRM3—nephrolithiasis	0.000354	0.00116	CbGpPWpGaD
Clomipramine—ALB—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000352	0.00115	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—AGXT—nephrolithiasis	0.000345	0.00113	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—DGKH—nephrolithiasis	0.000343	0.00112	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000343	0.00112	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	0.000341	0.00112	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000338	0.00111	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—PTH—nephrolithiasis	0.000324	0.00106	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000323	0.00106	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—RGS14—nephrolithiasis	0.000323	0.00106	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	0.000309	0.00101	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000308	0.00101	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GRHPR—nephrolithiasis	0.000305	0.000999	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000296	0.000968	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000294	0.000963	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000294	0.000961	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—SLC26A1—nephrolithiasis	0.000293	0.000959	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—APRT—nephrolithiasis	0.000293	0.000959	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000276	0.000905	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	0.000276	0.000905	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000274	0.000896	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AGXT—nephrolithiasis	0.000272	0.00089	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CHRM3—nephrolithiasis	0.000271	0.000888	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000269	0.000881	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—PTH—nephrolithiasis	0.000269	0.000879	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000267	0.000875	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000267	0.000875	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000252	0.000825	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PTH—nephrolithiasis	0.000248	0.000812	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CHRM3—nephrolithiasis	0.000248	0.000811	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—PTH—nephrolithiasis	0.000244	0.0008	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.000244	0.000799	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00024	0.000786	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—DGKH—nephrolithiasis	0.00024	0.000786	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000238	0.00078	CbGpPWpGaD
Clomipramine—ALB—Metabolism—SLC26A1—nephrolithiasis	0.000231	0.000757	CbGpPWpGaD
Clomipramine—ALB—Metabolism—APRT—nephrolithiasis	0.000231	0.000757	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PTH—nephrolithiasis	0.000227	0.000741	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000225	0.000735	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—DGKH—nephrolithiasis	0.000218	0.000715	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000218	0.000715	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GRHPR—nephrolithiasis	0.000213	0.000699	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—AQP1—nephrolithiasis	0.000209	0.000683	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000208	0.000679	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000208	0.000679	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000203	0.000663	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—APRT—nephrolithiasis	0.000203	0.000663	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	0.0002	0.000654	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000191	0.000625	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000191	0.000625	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AGXT—nephrolithiasis	0.00019	0.000623	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CHRM3—nephrolithiasis	0.000189	0.000618	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PTH—nephrolithiasis	0.000183	0.000598	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000174	0.000568	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AQP1—nephrolithiasis	0.000165	0.000539	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000165	0.000539	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—SPP1—nephrolithiasis	0.000162	0.000532	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—APRT—nephrolithiasis	0.000162	0.000529	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	0.000162	0.000529	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PTH—nephrolithiasis	0.000159	0.000519	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000158	0.000517	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CHRM3—nephrolithiasis	0.000149	0.000488	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.000148	0.000484	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000147	0.00048	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PTH—nephrolithiasis	0.000144	0.000473	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AQP1—nephrolithiasis	0.000144	0.000472	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000136	0.000445	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000134	0.000438	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CHRM3—nephrolithiasis	0.000131	0.000427	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000125	0.000409	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000125	0.000409	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—SPP1—nephrolithiasis	0.000125	0.000408	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000123	0.000403	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AQP1—nephrolithiasis	0.000115	0.000377	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—SPP1—nephrolithiasis	0.000114	0.000372	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CHRM3—nephrolithiasis	0.000104	0.000341	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	9.18e-05	0.0003	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AQP1—nephrolithiasis	8.89e-05	0.000291	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CHRM3—nephrolithiasis	8.04e-05	0.000263	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SPP1—nephrolithiasis	7.97e-05	0.000261	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SPP1—nephrolithiasis	7.25e-05	0.000237	CbGpPWpGaD
